SAGE Therapeutics (SAGE) PT Set at $170.00 by Oppenheimer

SAGE Therapeutics (NASDAQ:SAGE) has been given a $170.00 price target by stock analysts at Oppenheimer in a report issued on Sunday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 34.75% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. BidaskClub raised shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday. Canaccord Genuity set a $220.00 price target on shares of SAGE Therapeutics and gave the company a “buy” rating in a report on Thursday, November 1st. Cowen reissued a “buy” rating and set a $207.00 price target on shares of SAGE Therapeutics in a report on Thursday, November 1st. LADENBURG THALM/SH SH set a $235.00 price target on shares of SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 31st. Finally, Morgan Stanley boosted their target price on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $203.63.

Shares of SAGE stock opened at $126.16 on Friday. SAGE Therapeutics has a 12-month low of $61.67 and a 12-month high of $195.97. The stock has a market cap of $6.42 billion, a P/E ratio of -17.79 and a beta of 2.76.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter. On average, equities analysts predict that SAGE Therapeutics will post -7.32 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in SAGE. Dimensional Fund Advisors LP grew its position in shares of SAGE Therapeutics by 58.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 46,362 shares of the biopharmaceutical company’s stock worth $7,468,000 after buying an additional 17,044 shares during the period. Principal Financial Group Inc. grew its position in shares of SAGE Therapeutics by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after buying an additional 382 shares during the period. UBS Group AG grew its position in shares of SAGE Therapeutics by 242.6% during the 1st quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock worth $3,785,000 after buying an additional 16,636 shares during the period. Millennium Management LLC grew its position in shares of SAGE Therapeutics by 103.5% during the 1st quarter. Millennium Management LLC now owns 52,592 shares of the biopharmaceutical company’s stock worth $8,471,000 after buying an additional 26,747 shares during the period. Finally, Legal & General Group Plc grew its position in shares of SAGE Therapeutics by 3.7% during the 1st quarter. Legal & General Group Plc now owns 17,581 shares of the biopharmaceutical company’s stock worth $2,831,000 after buying an additional 629 shares during the period.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: Do closed-end mutual funds pay dividends?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply